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Abstract: 
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes an 
impairment in both the upper and lower motor neurons. The recent description of numerous non-motor signs 
points to an involvement of the neocortex networks that is more complex than was previously believed. 
Paired associative stimulation (PAS), a combination of transcranial magnetic stimulation (TMS) and 
peripheral nerve stimulation, can enhance motor output in the contralateral hand through an NMDA-
mediated sensorimotor mechanism.  
OBJECTIVE: To describe the effects of PAS on ALS patients before and after Riluzole intake compared 
with healthy subjects. 
METHODS: PAS was used to detect differences between 24 newly-diagnosed ALS patients and 25 age-
matched healthy controls. MEP amplitude from the abductor pollicis brevis was considered before PAS, 
immediately after (T0) and after 10 (T10), 20 (T20), 30 (T30) and 60 (T60) minutes. Statistical significance 
was calculated using RM-ANOVA. 
RESULTS: In healthy controls, PAS significantly increased MEP amplitude at T10, T20 and T30 (p<0.05). 
In ALS patients, a significant increase in MEP amplitude was also observed after 60 minutes (p<0.05), thus 
demonstrating NMDA-mediated enhanced facilitatory plasticity. After two weeks of riluzole intake, no MEP 
amplitude increase was evident after PAS at any time point. In three monomelic-onset ALS patients, 
sensorimotor facilitation was evident only in the hemisphere corresponding to the affected side and appeared 
in the opposite hemisphere when the patients manifested contralateral symptoms.  
CONCLUSIONS: PAS may be considered a useful tool when investigating NMDA-mediated neocortical 
networks in ALS patients and the modulation of such networks after anti-glutamatergic drug intake. 
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is considered a rare disease, with a reported worldwide 
incidence of between 1.5 and 2.7 per 100,000 people per year and a prevalence of 1 per 20,000 
[1,2]. It is an adult onset neurodegenerative disorder that causes a premature loss of motor neurons 
in the cerebral cortex, brainstem and spinal cord. While the aetiology of ALS is unknown, current 
evidence suggests that multiple interacting factors contribute to motor neuron injury in ALS. One of 
the hypothesized pathogenetic mechanisms is glutamate-driven excitotoxicity in the motor cortex 
[3]. A considerable amount of significance has recently been assigned to non-motor aspects of 
motor neuron disease, such as cognitive impairment [4], gastrointestinal dysfunction [5], small fiber 
neuropathy [6] and laryngeal sensitivity [7]. The aim of this trial was to investigate pathogenetic 
mechanisms in ALS that involve not only motor function but also the cortical networks, which are 
responsible for some of the non-motor signs in this disease. 
Until recently, the only approved therapy for ALS was Riluzole, an antiepileptic drug with 
numerous pharmacodynamic mechanisms, such as inhibition of persistent Na+ current, potentiation 
of calcium-dependent K+ current, inhibition of neurotransmitter release, inhibition of fast Na+ 
current, inhibition of voltage-gated Ca++ current and inhibition of voltage-gated K+ current [8]. The 
activation of Na+ current enhances NMDA receptor function [9]. Riluzole also acts on muscle Na+ 
channels in myotubes [10]. 
There has recently been a surge in interest in electrophysiological techniques that promote and 
investigate short-term changes in human cerebral cortex excitability; within this context, paired 
associative stimulation (PAS) has drawn attention both as a therapeutic intervention [11,12] and as 
an experimental method to investigate Hebbian principles of synaptic plasticity. In the prototypical 
form of PAS [13], a single electrical stimulus is directed to a peripheral nerve before a magnetic 
stimulus is delivered to the contralateral primary motor cortex (M1). The inter-stimulus interval is 
adjusted to ensure that inputs to M1 initiated by the afferent volley arising from the nerve 
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stimulation occur simultaneously with the magnetic stimulation. Repeated pairing of the two 
sources of stimulation (i.e. association) over an extended period of time increases the excitability of 
corticospinal projections from M1. A reduction in corticospinal excitability has been reported when 
the inter-stimulus interval is adjusted so as to allow a corollary of the afferent volley to reach M1 
after the magnetic stimulus [14]. 
This neuroplastic adaptation revealed by PAS appears to exhibit several of the criteria designated 
for long-term potentiation (LTP) and long-term depression (LTD): its effects evolve quickly, are 
reversible and persist beyond the period of stimulation [15,16]. Pharmacological agents that interact 
with NMDA-receptor activity interfere with the outcomes of PAS, thereby supporting the 
hypothesis that LTP-like changes are implicated [16]. In view of these properties, and the 
widespread belief that the alterations in excitability induced by PAS are restricted to cortical 
representations of the muscles innervated by the peripheral nerve that has been stimulated 
electrically, it has been suggested that PAS-induced adaptation represents a form of associative LTP 
(and LTD) that is synapse-specific [17] and behaves in accordance with Hebbian principles 
[13,18,19].   
Following the first description of this technique by Stefan and colleagues in 2000, there have been a 
wide range of derivative investigations concerning, among other features, the most effective inter-
stimulus intervals (ISIs) [20,21], the muscles in which the effects can be elicited [13,22,23] and 
variations in the extent to which they can be induced in various clinical populations [12]. As this 
corpus of work has accumulated, large inter-individual differences in response to PAS have been 
observed [24]. This has led to investigations on potential mediating factors such as age [25], cortical 
anatomy [26] and the role of specific genetic polymorphisms [27]. 
In this study, we used the PAS paradigm to test whether plasticity within the sensorimotor cortex is 
abnormal in ALS patients and to investigate the effects of Riluzole on the outcome of this 
stimulation. PAS was also used in three patients with monomelic onset to determine whether there 
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are any differences in cortical excitability between the two hemispheres. Two of these three patients 
were re-tested shortly after contralateral lower motor neuron signs had appeared. 
MATERIALS AND METHODS 
We recruited 24 newly-diagnosed patients affected by probable and definite ALS [28]. The patients’ 
demographic characteristics are shown in Table 1.  None of the patients were taking any specific 
therapy when they were recruited; any psychotropic drugs were suspended at least 2 weeks before 
the trial started. Twenty-five, healthy, age-matched controls were also tested. 
Every ALS patient was tested before and after taking 100 mg/die of Riluzole for two weeks. When 
PAS was performed while the patients were taking Riluzole, the drug was administered 12 hours 
before PAS so as to be able to investigate the chronic effects, as opposed to the acute effects, of 
Riluzole. In every subject, we measured the resting motor threshold (RMT), the sensory threshold 
over the median nerve of the non-dominant hand (assessed by means of the Edinburgh Handedness 
Inventory scale) at 500 µs of duration, the maximal motor evoked potential (MEP) and the mean 
MEP amplitude, which was based on 10 stimuli at 0.1 Hz at 120% of the RMT, delivered before 
PAS stimulation, immediately after (T0) and after 10 (T10), 20 (T20), 30 (T30) and 60 (T60) 
minutes. The RMT was defined as the lowest intensity able to evoke an MEP of more than 50 µV in 
at least 5 out of 10 consecutive trials in the abductor pollicis brevis (APB) of the non-dominant 
hand. Transcranial magnetic stimulation (TMS) was delivered through a high-frequency magnetic 
stimulator (Magstim Rapid – The Magstim Company Ltd, Whitland, South West Wales, UK) 
connected to a figure-of-eight coil. We also measured the N20 wave of the somatosensory evoked 
potential (SEP) in each patient. PAS stimulation consisted of 200 paired stimuli at 0.3 Hz. Magnetic 
stimuli were delivered over the hotspot for the APB of the non-dominant hand at 100% of the RMT. 
The coil was held tangentially to the scalp with the handle pointing back and away from the midline 
at 45°. Electrical stimulation was delivered over the median nerve of the non-dominant hand at 500 
µs of duration, at an intensity equivalent to 300% of the sensory threshold. The time between the 
electrical and magnetic stimuli (inter-stimulus interval - ISI) was calculated by adding 6 ms to the 
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N20 component of each patient. Previous studies have demonstrated that the ISI plays a key role in 
determining MEP amplitude changes after PAS [29], thereby highlighting the importance of 
personalizing this test. 
A PAS session was performed the following day in the 8 healthy controls using the same 
parameters (mean MEP amplitude evoked by 10 stimuli before PAS stimulation, immediately after 
(T0) and after 10 (T10), 20 (T20), 30 (T30) and 60 (T60) minutes), adopting a testing stimulus 
intensity of 110% instead of 120% of the RMT in order to ensure that the number of motor neurons 
activated did not affect the PAS.  
In three patients with monomelic ALS onset who presented first and second motor neuron 
involvement in the same upper limb, PAS was performed by stimulating the right and left cortex on 
two consecutive days while they did not take Riluzole. The diagnosis of probable or definite ALS 
was subsequently confirmed by disease progression. Two of these three patients did not take 
Riluzole and were tested again when signs of ALS appeared in the opposite arm. 
STATISTICAL ANALYSIS 
The mean RMT was calculated in the patient group before and after they took Riluzole as well as in 
the control group. Mann-Whitney for independent samples was used to compare the RMT 
amplitude in patients not taking Riluzole and in the control group. ANOVA for repeated measures 
(RM-ANOVA) was used to detect any effect of PAS on the absolute MEP amplitude immediately 
after PAS (T0) and 10 (T10), 20 (T20), 30 (T30) and 60 (T60) minutes later; a within-subject and 
between-subject analysis was performed to detect any variation in the mean MEP amplitude 
between pre-stimulation and post-stimulation values and between patients and controls. Corrections 
for the disease duration, cMAP amplitude from the median nerve of the non-dominant hand, 
ALSFRS-R score and product between ALSFRS-R score and disease duration were applied to the 
results when they significantly affected them. Statistical significance was set at p<0.05. All the data 
analyses were performed by means of IBM SPSS Statistics 22. 
RESULTS 
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The mean RMT in the patients before and after Riluzole intake as well as in the control group are 
shown in Table 2. The Mann-Whitney test revealed a markedly higher RMT in ALS patients than in 
age-matched controls (p<0.01), though no significant difference emerged between the pre- and 
post-Riluzole sessions (p>0.05). The MEP amplitude at 120% of RMT was higher in healthy 
controls than in ALS patients regardless of whether they took Riluzole, though the difference was 
not statistically significant. A one-way RM ANOVA was conducted to compare the effect of PAS 
on MEP amplitude at the different time points. Our data violated the assumption of sphericity for 
both controls and ALS patients regardless of whether the latter took Riluzole. The results of the RM 
ANOVA with a Huynh-Feldt correction showed that the mean MEP amplitude differed significantly 
at the different time points in the control group (F(3.173, 2.376) = 2.820, p < 0.05); no significant 
difference in MEP amplitude between the time points emerged in ALS patients regardless of 
whether they took Riluzole, although a trend to significance was detected in patients who did take 
Riluzole (p=0.064). The within-subject analysis performed in the control group demonstrated a 
significant post-stimulation increase in the mean MEP amplitude at T10 (p=0.027), T20 (p=0.040) 
and T30 (p=0.024) compared with the pre-stimulation mean MEP amplitude. The within-subject 
analysis in the ALS patients who did not take Riluzole revealed a significant increase in the mean 
MEP amplitude at T20 (p=0.036), T30 (p=0.017) and T60 (p=0.031) compared with the pre-
stimulation mean MEP amplitude. The within-subject analysis in ALS patients taking Riluzole 
demonstrated a significant decrease in mean MEP amplitude at T0 (p=0.009), T20 (p=0.042) and 
T30 (p=0.039) compared with the pre-stimulation mean MEP amplitude, with a trend to 
significance at T10 (p=0.077) and T60 (p=0.056) (fig.1). The between-subject analysis did not 
detect any significant difference between controls and ALS patients who did not take Riluzole; this 
finding is likely to be due to the small sample size. 
We also performed a within-subject analysis on the effect of PAS on the ratio between the MEP 
amplitude at different time points and the baseline MEP amplitude in order to exclude any effect of 
the baseline MEP amplitude on the results. The within-subject analysis performed in the control 
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group revealed a significant post-stimulation increase in the mean MEP amplitude at T10 
(p=0.001), T20 (p=0.022) and T30 (p=0.003); the within-subject analysis in ALS patients who did 
not take Riluzole also revealed a significant post-stimulation increase in the mean MEP amplitude 
at T20 (p=0.025), T30 (p=0.016) and T60 (p=0.013). 
The same statistical evaluations were performed in healthy controls, who were tested at 110% of the 
RMT intensity. No substantial differences were detected between this session and that performed at 
120% of the RMT intensity (when compared with pre-stimulation MEP values, values were 
statistically significant at T10, T20 and T30; respectively p=0.030, p=0.028, p=0.003). All the 
results of RM ANOVA were covariated for the disease duration, ALSFRS-R score, cMAP 
amplitude from the median nerve of non-dominant hand and product between disease duration and 
ALSFRS-R score, as a parameter of decline speed. None of these parameters significantly corrected 
the RM ANOVA results (p>0.05). 
In the three patients with monomelic upper limb onset, PAS was performed both on the affected and 
unaffected sides. On the affected side, MEP behaved in the same way as in ALS patients who did 
not take Riluzole, with an increase in amplitude that persisted for 60 minutes post-stimulation. By 
contrast, the unaffected side yielded an increase in MEP amplitude that disappeared by T60, thus 
resembling the behavior observed in healthy subjects (Fig. 2). Two of these three patients did not 
take Riluzole and were tested again, shortly after a contralateral loss of strength and EMG signs of 
peripheral involvement had appeared. The originally unaffected arm yielded the same results as the 
affected side (Fig. 3). 
DISCUSSION 
ALS is a rare disease with a non-defined etiology. Numerous theories on its causes have been 
proposed, ranging from genetic mutations [30,31] to inflammatory damage [32], mitochondrial 
dysfunctions [33] and ubiquitin-proteasome system alterations [34]. Many of these hypotheses 
converge upon an increase in glutamate levels, which results in excitotoxic damage mediated by 
NMDA-channels: the opening of this receptor generates a Calcium inflow, which activates caspases 
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and nitroxide synthase-mediated apoptosis. Increased glutamate levels and decreased glutamate 
transporter levels have been observed in the CSF of ALS patients [35,36,37]; glutamate leads to an 
increase in intracellular calcium levels, which in turn causes neuronal death. PET studies have 
revealed enhanced expression of NMDA receptors in ALS mouse models [38]. Riluzole, the only 
drug that has been approved for the treatment of ALS in many countries, has an anti-glutamatergic 
effect that is mediated by Na+ channel inhibition [5] and is considered to prevent excitotoxic 
damage [39,40]. Riluzole also exerts effects on a number of ion channel currents [8]. 
Human motor cortex excitability, as tested by means of a RMT assessment, is related to 
glutamatergic transmission via non-NMDA glutamatergic channels, such as AMPA and Kainate 
[41]. A reduced RMT has been observed in Alzheimer’s disease [42]. Some authors have reported 
that the RMT is higher in ALS patients than in healthy subjects, which confirms previous data by 
suggesting that cortical excitability is reduced in ALS [43]. Other authors have pointed out that 
ALS patients may even be affected by a reduced RMT, though this generally occurs in the early 
stages as a result of corticomotor neuron hyperexcitability induced by glutamate, i.e. before upper 
motor neurons signs appear [44]. Riluzole intake did not have any effect on the RMT in the sample 
enrolled in this study. PAS has been shown to represent a form of associative LTP that is synapse-
specific [17] and thus exploits a NMDA-mediated mechanism. In our study, PAS increased the 
mean MEP amplitude 10 minutes after stimulation in the control group, though this effect had worn 
off 60 minutes post-stimulation. Although no direct difference between ALS patients who did not 
take Riluzole and the control group emerged, a significant increase in mean MEP amplitude was 
observed after 20 minutes and persisted beyond 60 minutes in ALS patients regardless of their 
baseline MEP amplitude (Fig. 1a and 1b). When the same ALS patients underwent PAS two weeks 
after Riluzole intake, a paradoxical reduction in MEP amplitude was observed immediately after 
stimulation as well as 20 and 30 minutes post-stimulation, with the reduction approaching 
significance at the other time points. Similar results were observed when the MEP amplitude was 
tested in healthy subjects at a stimulation intensity corresponding to 110% of the RMT. This spin-
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off analysis was performed to simulate the effects of PAS on a reduced number of motor neurons, 
as occurs in ALS patients. The fact that the results yielded by both the 110% and 120% sessions 
were comparable demonstrates that the effects of PAS are not dependent on the number of motor 
neurons activated and consequently explain the similar results obtained in healthy subjects and ALS 
patients.  
All these data point to a reduction in AMPA and Kainate-mediated glutamatergic transmission, with 
greater NMDA-mediated facilitatory plasticity being observed in ALS patients than in the control 
group; indeed, the enhancing effect exerted by PAS on the MEP amplitude persisted 60 minutes 
post-stimulation (Fig. 1), whereas control group values at the same time point had returned to pre-
stimulation conditions. Two weeks of Riluzole intake did not modify non-NMDA glutamatergic 
channel-mediated RMT, but did break down NMDA-mediated enhanced facilitatory plasticity in 
ALS patients, who even presented a paradoxical reduction in MEP amplitude following PAS. We 
may also speculate that Riluzole exerts an effect on the Na+ channel, which would in turn impair 
NMDA receptor function [9]; this hypothesis is supported by findings in other studies, according to 
which some antiepileptic drugs that block the Na+ channel reduce cortical excitability by acting on 
NMDA-related mechanisms [45,46].   
The potential limitations of this study are the variability of the response to PAS and the lack of 
correlation between our results and Riluzole blood levels. Nevertheless, it should be borne in mind 
that the results were based on a cross-over trial in which the same patients were analyzed before and 
after Riluzole intake; moreover, the physicians ensured that Riluzole had been ingested regularly 
before every PAS session. Lastly, besides acting on the glutamatergic system, Riluzole has 
numerous other mechanisms of action that may modify the effects of PAS; nevertheless, the fact 
that PAS appears to induce NMDA-mediated LTP-like changes and that its effect is modified by 
other pharmacological agents that interact with NMDA-receptor activity [16] suggests that the most 
important of the effects exerted by Riluzole on PAS is due to the anti-glutamatergic mechanism of 
this drug. Finally, other authors demonstrated that sodium and calcium channel blockers without 
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considerable neurotransmitter properties (carbamazepine, lamotrigine, losigamone) elevated RMT 
but did not change intracortical excitability [47]. Riluzole did not elevated RMT, thus excluding a 
relevant effect on ion channels. 
 Other authors have described alterations in intracortical plasticity in ALS patients, with a decrease 
in short interval intracortical inhibition (SICI) and an increase in intracortical facilitation (ICF) 
being reported [48,49,50]. In our study, we observed an increase in plasticity involving the sensory 
and motor areas in ALS patients that disappeared after Riluzole intake, which thus confirms the 
protective role of this drug. 
Facilitation of plasticity in a network that is highly complex, as is the sensorimotor network, may 
also explain some of the non-motor signs described in motor neuron diseases, such as behavioral 
and cognitive changes [51]. 
PAS was delivered over both hemispheres in three ALS patients with monomelic onset to 
investigate any differences between the affected and unaffected side. A diagnosis of either probable 
or definite ALS was subsequently confirmed in all three patients. Given the rarity of this condition 
and the small sample we studied, no statistical analysis could be performed; nevertheless, the trend 
in MEP amplitude after PAS in all three patients resembled that observed on the unaffected side in 
healthy subjects and on the affected side in ALS patients who did not take Riluzole (Fig. 2). 
A dying-back phenomenon has been observed in many ALS mouse models, with an early 
involvement of the muscle and neuromuscular junction that subsequently spreads to the second and 
first motor neurons [52,53,54]. An MRI and histological study on G93A-SOD1 mice revealed an 
early reduction in muscle volume but visible alterations in M1 cortex only considerably later [55]. 
Other authors have instead hypothesized a dying-forward model, with a reduction in SICI and an 
increase in ICF preceding lower motor neuron impairment [56]. Moreover, Fogarty observed an 
increase in dendritic spine density in the pyramidal motor neurons of ALS patients, thereby 
explaining the increased excitatory neurotransmission [57]. In our small sample of monomelic onset 
patients, the unaffected side may be considered as a pre-symptomatic model of disease; indeed, the 
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loss of focal strength loss in all three patients began with peripheral features, including muscle 
atrophy and fasciculations. Upper motor neuron signs in the same arm only appeared later, thus 
pointing to a dying-back mechanism in such patients. PAS in these monomelic patients induced a 
behavior that was similar to that observed in other ALS patients on the affected side and in healthy 
controls on the unaffected side. When the initially unaffected side was tested again in two patients 
following the appearance of loss of strength, the findings were similar to those observed on the 
opposite side, thus suggesting that changes in sensorimotor network plasticity do not precede lower 
motor neuron signs. 
We may speculate that the disease is transmitted between the upper and lower motor neurons in 
various ways that are dependent on the onset, though further investigations are needed to shed light 
on this hypothesis. 
 
CONCLUSION 
In this study, PAS showed that facilitatory plasticity of the sensorimotor network is greater in ALS 
patients than in healthy subjects; this effect disappears after Riluzole intake, thereby confirming 
glutamate toxicity in this pathology. In monomelic patients, the effects of PAS on the affected side 
were found to be the same as those observed in ALS patients, while those on the unaffected side 
were the same as those observed in healthy controls. Enhanced plasticity of the sensorimotor 
network cannot, therefore, be considered to precede lower motor neuron signs in these monomelic 
patients. To sum up, PAS should be taken in consideration as a tool to check the efficacy of new 
anti-glutamatergic drugs and to improve the diagnostic approach to motor neuron diseases. 
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Tab. 1 Demographic characteristics of ALS patients. 
  
Age (years) 68 (±8.6) 
Gender (M/F) 16/8 
ALSFRS-R score 39.9 (±4.8) 
Disease duration (months) 17.2 (±13.7) 
Median cMAP amplitude (mV) 8.1 (±3.7) 
 
 
Tab. 2 MEP amplitude±SEM before and after PAS (T0, T10, T20, T30 and T60) in healthy controls 
and ALS patients without and with Riluzole, stimulated at 110 and 120% of RMT. 
 
 
 
 
 
 
 
 
 
 
 
 
 Healthy subjects ALS Patients 
  Without Riluzole With Riluzole 
 
RMT  59.96±2.53 70.14±2.69 68.50±2.90 
MEP pre-stimulation 0.87±0.17 0.50±0.13 0.48±0.11 
MEP T0 0.93±0.18 0.47±0.13  0.38±0.10* 
MEP T10  1.14±0.21* 0.75±0.20 0.39±0.09 
MEP T20  1.11±0.24 *  0.70±0.19*  0.38±0.11* 
MEP T30  1.30±0.27 *  0.70±0.18*  0.37±0.09* 
MEP T60 0.94±0.17  0.68±0.15* 0.41±0.10 
MEP pre-stimulation 110% 0.32±0.14   
MEP T0 110% 0.37±0.15   
MEP T10 110%  0.98±0.30*   
MEP T20 110%  0.61±0.19*   
MEP T30 110%  0.65±0.14*   
MEP T60 110% 0.36±0.14   
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Fig. 1a and b: Absolute (a) and normalized (b) MEP amplitude before and after PAS (T0, T10, T20, 
T30 and T60) in healthy controls and ALS patients without and with Riluzole. * p<0.05, compared 
with pre-stimulation.  
  
Fig. 2: Normalized MEP amplitude before and after PAS (T0, T10, T20, T30 and T60) in affected 
and unaffected side of three monomelic onset patients not taking Riluzole. 
 
Fig. 3: Normalized MEP amplitude before and after PAS (T0, T10, T20, T30 and T60) in two 
monomelic onset patients: comparison between the same arm before and after developing lower 
motor neuron signs. 
 
None of the authors disclose any financial and personal relationships with other people or 
organizations that might bias this study. This clinical trial was approved by the local ethics 
committee and respected the declaration of Helsinki.  
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- Integrative networks in ALS are evaluable by paired associative stimulation (PAS) 
 
- The MEP amplitude increase after PAS lasts one hour in ALS, 30 minutes in controls 
 
- Riluzole assumption nullifies MEP increase in ALS patients 
 
- Integrative networks are facilitated in ALS patients by glutamatergic mechanisms 
